Affilogic is a private biotech company specialized in discovering and developing Nanofitins^® through early-stage collaborations with worldwide industry leaders in the pharmaceutical sector.

These affinity proteins can be designed as targeted inhibitors, or as vectors for specific addressing of cells and tissues. Affilogic follows the science to any therapeutic area as long as an innovative Nanofitin-based biotherapy can make a difference to meet patients’ needs. Usual systemic routes can be travelled by Nanofitins^®, but their intrinsic properties make them amenable to other routes, such as oral route and pulmonary delivery.

Its operations are currently largely conducted through international collaborations with pharma and biotech companies, and through internal R&D programs, for some of them partially sponsored by public funding (France Relance/ French Government, Eurostars / European Commission and BPI, FEDER React EU / European Commission and Région Pays de La Loire…).

Affilogic is also extremely well integrated in its local environment, as a major member of the Atlanpole Biotherapies cluster in Nantes, one of the few French bio-clusters recognized by the government for its specific expertise in biotherapies and development of biotherapeutics. The company has signed a general collaboration framework agreement with the University of Nantes.